Will Your Next FDA or EMA Question Delay Approval?

Will Your Next FDA or EMA Question Delay Approval? Why Small Pharma Companies Need to Prepare Before Regulators Ask 

A regulatory submission is often viewed as the finish line after years of development, manufacturing scale-up, analytical testing, and documentation efforts.

The dossier is submitted. The review clock starts. Teams shift their attention to the next milestone.

Then the questions arrive.

The FDA requests additional justification for specifications. The EMA seeks clarification on process validation strategy. Health Canada asks for further comparability evidence. MHRA raises concerns about impurity qualification. Another authority requests supporting rationale behind a critical manufacturing decision made years earlier.

What begins as a routine regulatory query can quickly become a high-pressure exercise involving Regulatory Affairs, CMC, Quality, Manufacturing, Analytical Development, Stability, and Supply Chain teams.

For many small and mid-sized pharmaceutical and biotechnology companies, the problem is not that regulators ask questions.

The problem is that companies often begin preparing their scientific defence only after receiving those questions.

The most successful organizations are not necessarily the ones that respond the fastest. They are the ones that have already prepared the answers before regulators ask.

The Hidden Cost of Regulatory Questions

For large pharmaceutical organizations, health authority interactions are supported by extensive regulatory intelligence teams, subject matter experts, and dedicated response management functions.

A single agency inquiry can trigger:

• Cross-functional data gathering across multiple departments
• Retrieval of historical development records and decisions
• Scientific justification development under tight timelines
• Resource diversion from ongoing projects
• Multiple internal review cycles
• Delayed response submissions
• Increased likelihood of follow-up questions

The impact extends beyond regulatory timelines.

A delayed response can affect:

• Product launch schedules
• Commercialization plans
• Investor confidence
• Partnership commitments
• Revenue forecasts
• Market access opportunities

In today’s competitive environment, regulatory delays can become business delays.

The Reality We See Every Day During Health Authority Reviews

Across global submissions, many health authority questions arise from recurring gaps that could have been anticipated earlier.

Common challenges include:

Limited Scientific Rationale

Data may exist, but the scientific justification behind critical decisions is often poorly documented.

Reviewers frequently ask:

Why was a particular specification selected?

How were acceptance criteria established?

What risk assessment supports the control strategy?

Why was a specific test method chosen?

Organizations often spend weeks reconstructing decisions that were made years earlier.

Inconsistent Information Across Submission Documents

One of the most frequent observations involves inconsistencies between:

• Module 2 summaries
• Module 3 CMC sections
• Validation reports
• Stability reports
• Analytical method documentation

Even minor inconsistencies can trigger additional clarification requests.

Weak Linkage Between Development Data and Commercial Controls

Health authorities increasingly expect sponsors to demonstrate how development knowledge translates into commercial manufacturing controls.

Common reviewer concerns include:

• Process understanding
• Critical Quality Attributes (CQAs)
• Critical Process Parameters (CPPs)
• Control strategy justification
• Risk-based decision making
• Gaps in Lifecycle Management Planning

Reviewers want confidence that product quality can be maintained throughout a product’s lifecycle.

Frequently questioned areas include:

• Post-approval change management
• Continued process verification
• Stability commitments
• Comparability strategies
• Ongoing process monitoring

Case Study: Preparation That Saved Valuable Review Time

A growing biotechnology company was preparing its first global marketing application.

While assembling the dossier, the team recognized several areas likely to attract regulator attention:

• Product specifications
• Analytical methods
• Manufacturing controls
• Process validation
• Stability strategy
• Critical Control strategies

Rather than waiting for questions, the company took a proactive approach.

Prior submission, they:

• Developed scientific rationale documents for critical CMC decisions
• Created structured evidence packages
• Conducted reviewer-focused gap assessments
• Mapped supporting data to likely agency concerns
• Organized historical development knowledge into readily accessible repositories

When health authority questions eventually arrived, the organization was prepared.

The supporting evidence already existed.

The rationale had already been documented.

The responses could be assembled efficiently and consistently.

The Outcome

Instead of spending valuable review time searching for information, teams focused on delivering clear and scientifically compelling responses.

The difference was not better data.

The difference was better preparedness.

“What Regulators Are Really Looking For”

Whether the review is conducted by FDA, EMA, MHRA, Health Canada, PMDA, TGA, or another authority, reviewers are asking a common question:

“Does the sponsor truly understand the product and process?”

Regulators evaluate whether an organization can scientifically justify its decisions and consistently assure product quality.

Key focus areas include:

• Manufacturing process understanding
• Product specifications
• Analytical method validation
• Stability strategy
• Impurity control
• Control strategy development
• Process validation
• Comparability assessments
• Risk management
• Lifecycle management planning

The concern is rarely whether data exists.

The concern is whether the sponsor can clearly explain and defend what the data means.

When scientific rationale is weak, questions increase.

When rationale is robust and evidence-based, reviewer confidence grows.

A Strategic Shift: From Response Management to Question Readiness

Leading organizations are changing the way they think about regulatory reviews.

Instead of asking:

“How will we answer health authority questions?”

They ask:

“What questions are regulators likely to ask, and have we already prepared our scientific defense?”

This mindset enables organizations to:

• Reduce review-cycle delays
• Improve consistency in responses
• Increase reviewer confidence
• Strengthen submission quality
• Accelerate approvals
• Optimize limited internal resources

Most importantly, it transforms regulatory review from a reactive exercise into a controlled and strategic process.

How Celegence Helps Sponsors Stay Ahead

At Celegence Systems, we help pharmaceutical and biotechnology organizations strengthen regulatory and CMC readiness before health authority questions arise.

Our experts support sponsors through:

CMC Defence Readiness

• Scientific rationale development
• Technical justification authoring
• Control strategy documentation
• Risk-based assessment support

Submission Readiness Evaluations

• Dossier gap assessments
• Reviewer-focused mock reviews
• Submission consistency reviews
• Cross-module alignment checks

Regulatory Query Preparedness

• Response strategy development
• Evidence package creation
• Health authority response support
• Global submission harmonization

Lifecycle Management Support

• Post-approval change management
• Comparability planning
• Continued process verification support
• Regulatory impact assessments

By combining deep CMC expertise with practical regulatory experience, Celegence helps organizations identify potential vulnerabilities before they become agency questions.

The Best Time to Prepare Is Before the Question Arrives

Regulatory questions are inevitable.

Regulatory delays are not.

Organizations that invest in CMC readiness, scientific justification development, and proactive regulatory planning are significantly better positioned to navigate reviews with confidence.

Because when the FDA, EMA, MHRA, Health Canada, or another global authority asks a question, the goal should not be to start looking for an answer.

The goal should be to already have one.

Ready to Strengthen Your Submission Readiness?

Whether you’re preparing an NDA, BLA, MAA, post-approval variation, lifecycle submission, or a global regulatory strategy, Celegence can help you build the scientific rationale, evidence packages, and regulatory readiness framework needed to stay ahead of health authority expectations.

Connect with Celegence’s Regulatory and CMC experts today and turn regulatory uncertainty into regulatory confidence.

Talk to Our Global CMC Experts →